Evonik eyes growth in Philippines with expansion of local office
- The new Philippines office will strengthen the company’s 20-year presence in the country, becoming Evonik’s latest legal entity in the region
- Evonik to focus in building closer ties to new and existing customers in the Philippines
Evonik, one of the world leaders in specialty chemicals, inaugurates its new office in Manila today. With a legal entity in the county, Evonik will bring further focus in establishing market leadership and forging stronger business ties with its potential and existing customers in the Philippines.
The new office, located at the financial business district of Bonifacio Global City (BGC) in Taguig, officially becomes the latest addition to Evonik’s existing legal entities across Asia Pacific South - a significant milestone after 20 years since its first representative office opened in the Philippines in 1997.
“Our decades-long presence in the Philippines and its developing dynamic business landscape, represent the increasing importance of this market in supporting our regional business growth,” said Peter Meinshausen, Regional President of Evonik Asia Pacific South, in the Philippines today. “The opening of our new office marks another significant achievements of Evonik, I look forward to broadening and deepening our customer relationships in the country, and continue to build on the success that we have achieved over the past 20 years.”
Evonik’s office in the Philippines is engaged in managing business relations for its various business lines including animal nutrition, household care, personal care, silica, silanes, coating additives, high performance polymers, acrylic polymers and functional solutions. Having established close partnerships with some of the key players in the country’s progressive poultry and swine industry, Evonik’s innovative products and solutions for animal nutrition currently forms the company’s largest market growth in the Philippines. With its new legal entity, Evonik also sees a market potential for some of its product portfolio to grow in the country.
Evonik Philippines is a wholly-owned subsidiary of Evonik Industries. Active in over 100 countries around the world, Evonik has a strong brand portfolio for multiple industry applications including but not limited to health care, animal nutrition, resource efficiency, and performance materials.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, high innovative prowess and an encouraging and trustful corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2016, the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.
Evonik Asia Pacific South
Headquartered in Singapore, Evonik is present in the Asia Pacific South region with production sites, sales offices, innovation and technical service centers located in Australia, Bangladesh, India, Indonesia, Malaysia, New Zealand, Pakistan, Philippines, Singapore, Thailand and Vietnam. With more than 1,600 employees in the region, the company steadily grows its footprint in Asia Pacific South by expanding its regional operations in response to the growing demand. Evonik Industries has been establishing customer relationships and importing a broad range of products in the Asia Pacific South region since the 1920’s.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.